Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Sulfadiazine, silver [USAN:USP]
RN: 22199-08-2
UNII: W46JY43EJR
InChIKey: UEJSSZHHYBHCEL-UHFFFAOYSA-N

Note

  • Antibacterial used topically in burn therapy.

Molecular Formulas

  • C10-H10-N4-O2-S.Ag
  • C10-H9-Ag-N4-O2-S

Molecular Weight

  • 357.1431
 

Classification Codes

  • Anti-Infective Agents
  • Anti-Infective Agents, Local
  • Anti-Infective, Topical
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Silver sulfadiazine
  • Sulfadiazine silver salt
  • Sulfadiazine, silver [USAN:USP]

MeSH Heading

  • Silver sulfadiazine

Synonyms

  • 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
  • Dermazin
  • Dermazine
  • EINECS 244-834-5
  • Flamazine
  • Geben
  • N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
  • N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
  • NSC 625324
  • Silbertone
  • Silvadene
  • Silver sulfadiazine
  • Silver sulphadiazine
  • SSD
  • SSD AF
  • Sulfadiazin silber
  • Sulfadiazin, silbersalz
  • Sulfadiazine silver
  • Sulfadiazine silver salt
  • Sulfadiazine, Silver
  • Sulfolex
  • Thermazene
  • UNII-W46JY43EJR

Systematic Names

  • (4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
  • Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
  • Silver, (4-amino-N-2-pyrimidinylbenzenesulfonamidato-NN,O1)-
  • Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt

Mixture Name

  • SSD

Registry Numbers

CAS Registry Number

  • 22199-08-2

FDA UNII

  • W46JY43EJR

System Generated Number

  • 0022199082

Molecular Formulas

Molecular Formulas

  • C10-H10-N4-O2-S.Ag
  • C10-H9-Ag-N4-O2-S

Molecular Formula Fragments

  • Ag
  • C10-H10-N4-O2-S
  • COMPONENT

Structure Descriptors

InChI

1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1

InChIKey

UEJSSZHHYBHCEL-UHFFFAOYSA-N

Smiles

c1cnc(nc1)[N-]S(=O)(=O)c2ccc(cc2)N.[Ag+]

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo skin 536mg/kg/21W- (536mg/kg) PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) Lancet. Vol. 340, Pg. 126, 1992.
mouse LDLo intraperitoneal 550mg/kg (550mg/kg)   United States Patent Document. Vol. #4020150,
mouse LDLo oral > 10gm/kg (10000mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
mouse LDLo oral > 10gm/kg (10000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
mouse LDLo subcutaneous > 10gm/kg (10000mg/kg) BLOOD: CHANGES IN SPLEEN

LIVER: OTHER CHANGES
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
rat LD50 intraperitoneal 126mg/kg (126mg/kg) BLOOD: CHANGES IN SPLEEN

LIVER: OTHER CHANGES

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.
rat LD50 oral > 10gm/kg (10000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 637, 1982.
rat LD50 unreported 160mg/kg (160mg/kg)   United States Patent Document. Vol. #4535078,
rat LDLo subcutaneous > 10gm/kg (10000mg/kg) LIVER: OTHER CHANGES

BLOOD: CHANGES IN SPLEEN
Kiso to Rinsho. Clinical Report. Vol. 14, Pg. 2850, 1980.